Read More

4D Molecular Therapeutics Reports Interim Results From Phase 1/2 Trial Of Its Fabry Disease Candidate: ‘AGA enzyme activity was within, or significantly above, the normal range in all three patients’

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA enzyme activity was

FDMT

Read More

4D Molecular Therapeutics Early Sunday Highlighted Presentation Of Interim Results From Ongoing 4D-125 Phase 1/2 Trial In Patients With Advanced X-Linked Retinitis Pigmentosa At American Society Of Retina Specialists Meeting

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammation   Clinical activity observed through anatomical

FDMT